Efficacy of CAR-T administered close to a treatment by anti-CD19 antibody

Home > Lysa > Browse the current clinical studies > DESCAR-T, National Registry for Patients with Hematological malignancies, Eligible for CAR T-Cell Therapy > Research projects > Research projects with the registry data > Completed projects > Efficacy of CAR-T administered close to a treatmen...

The DESCAR-T registry was set up at the request of the health authorities to improve our knowledge of CAR-T cell therapies marketed in France to treat patients diagnosed with hematological malignancies. The objective of this registry is to collect data on the efficacy as welle as on short- and long-term tolerance of these therapies in real-life setting.

The registry data really enables the realization of projects to answer specific research questions. The project described here focuses on patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who received a treatment by anti-CD19 antibodies, such as Tafasitamab, before or after a treatment by CAR-T cells.

Why is this project being implemented?

In DLBCL, cancer cells usually carry on their surface a type of proteins (antigens) called CD19 marker. Anti-CD19 antibodies recognize this marker. The same is true for CAR-Ts, which are the patient’s own cells (T-lymphocytes or T-cells) modified to recognize the CD19 marker on tumor cells.

This project aims to bring more knowledge to hematologists who wish to offer CAR-Ts or anti-CD19 antibodies to their patients about the order or spacing between two treatments of these types.

What are the objectives of this project?

This project will analyze the efficacy of anti-CD19 CAR-Ts when administered close to a treatment by anti-CD19 antibodies, and the efficacy of anti-CD19 antibodies when administered close to a treatment by anti-CD19 CAR-Ts. The tolerance of these treatments will also be analyzed. The results will be compared to those of comparable patients who received other types of treatment before or after CAR T-cells.

How will the project be carried out?

The project is led by hematologists at the Henri Becquerel Treatment Center. It will use data from the medical records of patients diagnosed with DLBCL included in the DESCAR-T registry before September 2022.

The study is carried out in collaboration with the INCYTE laboratory. INCYTE will only receive descriptive reports without individual data No link can be made between the data contained in the reports and the patients participating in DESCAR–T.
A communication of the results is planned at a scientific congress.

 

 

FOR PATIENTS HAVING RECEIVED CAR-T IN FRANCE

What does this project involve for you?

This project uses the data of patients included in the DESCAR-T registry, i.e. patients who have received CAR-T treatment in France, and who have been diagnosed with DLBCL.

If you are in this situation and you accept that your data will be used for this project, this has no direct implication for you.

What should you do about this project?

There are two options:

  • You do not object to the use of your data for this project:

→ In this case, you do not have to do anything.

  • You wish to object to the use of your data in this project:

→ In this case, please inform the doctor at the center where you have received your CAR-T treatment. You can also notify your decision by email at: dpo@lysarc.org.

You can find more information about your rights to object to the use of your data on the page “I am participating or have participated in a clinical trial“.